[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BPharmCatalyst Avatar @BPharmCatalyst BioPharmCatalyst

BioPharmCatalyst posts on X about $imab, $sprb, $telo, $glto the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence cryptocurrencies XXXX% finance XXXX% stocks XXXX%

Social topic influence $imab #7, $sprb #36, $telo 0.88%, $glto #30, $xbio #10, $evax #3, $bjdx #27, $rapp 0.44%, $dnth 0.44%, $smmt XXXX%

Top accounts mentioned or mentioned by @yusufhameed @beallucanbe3 @artsstocks @ti60123bg @marketwirenews @hivolbreakouts @thenorthstar5 @streetcred2017 @meyer_adri74674 @varro_analytics @brantandre88074 @henrywalke70493 @aponiaanalytics @ripster47 @augustine_astr @asset_smind @ceciliacas81917 @seanluomdphd @clairefarrngoat @ranchitup42069

Top assets mentioned Summit Therapeutics Inc. Common Stock (SMMT) IDEAYA Biosciences, Inc. Common Stock (IDYA) Immunovant, Inc. Common Stock (IMVT) Vaxcyte, Inc. Common Stock (PCVX) Curate (XCUR) Bio Protocol (BIO) Avantor, Inc. (AVTR) Huma Finance (HUMA) Boston Scientific Corporation (BSX) Tourmaline Bio, Inc. Common Stock (TRML) CheckDot (CDT) Akropolis (AKRO) Apogee Therapeutics, Inc. Common Stock (APGE) Scholar Rock Holding Corporation Common Stock (SRRK) BOLT Token (BOLT)

Top Social Posts #

Top posts by engagements in the last XX hours

"$RAPP announced that its lead candidate RAP-219 met primary and key secondary endpoints in a Phase 2a trial for drug-resistant focal onset seizures demonstrating a XXXX% median seizure reduction and XX% seizure freedom with strong safety and tolerability. $DNTH $SMMT $IDYA $SINT $EDAP $XAIR See More Pre-market Movers"
X Link @BPharmCatalyst 2025-09-08T12:40Z 30.4K followers, 3558 engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next X months $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM"
X Link @BPharmCatalyst 2025-10-11T14:18Z 30.4K followers, 1850 engagements

"$XCUR 's GPC-100 study for stem-cell mobilization in multiple myeloma patients completed its Phase X with topline data expected in Q4 2025. Its fast dosing could simplify logistics with plans for AML and partnerships in cell/gene therapy. See More Biotech Updates👇 $FDMT $TNON $NRSN $BTAI $IMAB $BIO $XCUR $AVTR"
X Link @BPharmCatalyst 2025-08-01T20:40Z 30.4K followers, 2018 engagements

"$SPRB shares closed up after the FDA granted Breakthrough Therapy designation to tralesinidase alfa for Sanfilippo Syndrome Type B a rare pediatric neurodegenerative disorder. The company plans to file for U.S. approval in the first quarter of 2026. $SPRB $BMEA $HUMA $TELO $LXEO $LPTX $GLTO $XBIO $EVAX $CLRB See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-07T20:32Z 30.4K followers, 2255 engagements

"$ELUT agreed to sell its cardiac device business to Boston Scientific for $88M enabling debt elimination and a strategic shift toward its breast reconstruction-focused SimpliDerm franchise and drug-eluting pipeline aiming to improve financial stability and preserve shareholder value without dilution. $TRML $ELUT $CELU $RENB $REVB $TELO $XLO See More Biotech Updates👇 link"
X Link @BPharmCatalyst 2025-09-09T20:30Z 30.4K followers, 1881 engagements

"$CDT announced a 1-for-8 reverse stock split approved by its board aiming to enhance capital-raising flexibility as part of its strategic execution following prior shareholder authorization granted in May 2025. $BJDX $CDT $AKRO $APGE $ATHE $NGNE $TCRT $BDRX $PCSA $GTBP See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-09T12:40Z 30.4K followers, 1950 engagements

"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-15T12:40Z 30.4K followers, 11.6K engagements

"$NDRA secured $XXX million in a private placement led by institutional and crypto investors selling stock and warrants at $XXXX per unit to fund a digital asset treasury strategy focused on Arcas high-conviction DeFi holdings marking a pivot toward blockchain-linked capital deployment alongside its core MASLD/MASH imaging focus. $TRVD $CGEN $RCUS $MNPR $NDRA $SRRK $NBTX $APLT $QNRX $ADTX See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-13T20:30Z 30.4K followers, 1901 engagements

"$ARMP reported topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02 a novel IV administered multi-phage therapeutic for the treatment of S. aureus bacteremia (SAB) in the ITT population. The study showed that all primary endpoints for safety tolerability and clinical response in the intent-to-treat population were met. See More Biotech Updates👇 $PTIX $CVM $RGNX $NVAX $SKYE $QNTM $GUTS $XRTX $APLT"
X Link @BPharmCatalyst 2025-05-19T20:53Z 30.4K followers, 1775 engagements

"$SPRB secured $50M in a private placement to fund advancement of tralesinidase alfa for Sanfilippo Syndrome Type B (MPS IIIB) through BLA submission in Q1 2026 targeting a potential U.S. commercial launch by late 2026. $ESPR $SPRB $KPTI $RNAZ $VRCA $RBOT $XBIO $ACXP $GLTO $BJDX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-08T12:40Z 30.4K followers, 2971 engagements

"$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC 2025 complementing upcoming two-year efficacy results from its Phase X KEYTRUDA combination trial being presented at ESMO 2025. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-03T20:30Z 30.4K followers, 3349 engagements